Articles tagged with 'Women's Health' | Bayer

Newsroom Bayer (Women's Health)

2022
August
18,
2022
| 14:30 PM Europe/Amsterdam
Mirena®, Bayer’s long-acting reversible intrauterine system, now approved by U.S. FDA for up to eight years in contraception / Mirena (52mg LNG IUS) now offers the longest contraceptive duration of use for any hormonal intrauterine system / The IUS i...
Read more
2021
October
05,
2021
| 08:30 AM Europe/Amsterdam
Supports Bayer’s global sustainability commitment of providing 100 million women in low- and middle-income countries (LMICs) with access to modern contraception by 2030 / Investment in new production capabilities in Alajuela, Costa Rica and Turku, Fi...
Read more
September
26,
2021
| 08:00 AM Europe/Amsterdam
The ‘Your Right to Plan’ campaign aims at improving family planning and reproductive health services to Egypt’s underserved communities / The five-year partnership involves a total donation of EUR 330,000 / The program provides access to medical serv...
Read more
August
31,
2021
| 14:30 PM Europe/Amsterdam
Elinzanetant is an innovative non-hormonal development compound investigated for the treatment of vasomotor symptoms during menopause...
Read more
2020
November
18,
2020
| 08:30 AM Europe/Amsterdam
Focus on fostering development of integrated healthcare solutions in fields of cardiometabolic and renal diseases, oncology, and women’s health / Germany’s Federal Minister of Health Jens Spahn to give keynote at the virtual digital health forum "G4A...
Read more
September
09,
2020
| 08:30 AM Europe/Amsterdam
Berlin, Germany, September 9, 2020 - Bayer, a global leader in women’s healthcare, today announced that, further to its press release of August 11, 2020, it has now completed the acquisition of UK-based biotech company KaNDy Therapeutics Ltd. to expa...
Read more
August
20,
2020
| 19:00 PM Europe/Amsterdam
Leverkusen, August 20, 2020 - Bayer announced today that it has reached agreements with plaintiff law firms to resolve approximately 90% of the nearly 39,000 total filed and unfiled U.S. Essure™ claims involving women who allege device-related injuri...
Read more
August
11,
2020
| 08:30 AM Europe/Amsterdam
Further expansion of Bayer’s drug development pipeline in Women’s Healthcare / Innovative non-hormonal oral compound NT-814 to alleviate menopausal symptoms / Development compound recently completed Phase IIb / Reinforces Bayer’s position in Women’s ...
Read more
January
13,
2020
| 13:00 PM Europe/Amsterdam
Underlining Bayer’s commitment in the field of women’s health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit range...
Read more
2018
December
20,
2018
| 09:00 AM Europe/Amsterdam
Berlin, December 20, 2018 - Bayer announced today that Visanne™ has been approved by the Chinese regulatory authorities for the treatment of endometriosis. Visanne is a once-daily oral tablet containing dienogest 2 mg that has been developed specific...
Read more
2017
July
03,
2017
| 08:30 AM Europe/Amsterdam
Berlin, July 3, 2017 - Bayer announced today that the first patient was enrolled in a Phase III clinical study program ASTEROID which will investigate vilaprisan in women suffering from uterine fibroids. Vilaprisan, discovered at Bayer, is a novel or...
Read more